Navigation Links
BioMarin Acquires ZyStor Therapeutics, Inc.
Date:8/17/2010

NOVATO, Calif., Aug. 17 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders.  ZyStor's lead product candidate is ZC-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease.

Under the terms of the agreement, BioMarin acquired ZyStor for $22 million upfront and up to an additional $93 million if certain development, regulatory and commercial milestones are achieved. There are no royalties owed.  The FDA has accepted an investigational new drug (IND) application for ZC-701, investigational product has been manufactured and a clinical study is expected to start in Q1 2011.

In vitro studies demonstrate that ZC-701 has more than ten times higher affinity for the mannose-6-phosphate receptor compared to Myozyme, which enables delivery of higher levels of enzyme to the lysosomes of muscle cells of Pompe patients.  Studies in the Pompe mouse model indicate that ZC-701 clears glycogen to lower levels in skeletal, heart and diaphragm muscle compared to Myozyme and at similar levels compared to second generation compounds that have been tested.  Many experts believe that an enzyme with more efficient uptake into muscle cells would lead to more effective treatment of the disease.  Over the next several months BioMarin plans to recruit clinical research hospitals that can conduct clinical studies and finalize the clinical protocol and expects the first patient dosed in the first quarter of 2011.

"The acquisition of ZyStor gives us the opportunity to introduce a superior product to fulfill an unmet medical need and is a perfect fit in our core business.  It not only
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron ... (EURONEXT: SAN and NYSE: SNY ) today ... alirocumab in people with hypercholesterolemia met their primary efficacy ... low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared to ... antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... July 30, 2014  DigiPath, Inc. (OTCBB and OTCQB: ... into the cannabis testing and education markets, announced today ... and affairs not previously disclosed or, to its knowledge, ... market action. "We have noticed unusual price ... three trading days," said Steve Barbee , CEO ...
(Date:7/30/2014)... Coordinators, Inc. (PCI) is pleased to announce it has ... Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug development ... manufacturing, as well as Clinical Packaging, Labeling, and global ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8DigiPath No New Corporate Developments 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5
... 19, 2011 Families of Spinal Muscular Atrophy announced today ... and Drug Administration to commence a Phase I safety study ... being developed for Spinal Muscular Atrophy. FSMA ... stages of drug development, when risk is the highest.  It ...
... PRNewswire / -- Silicon Valley Bank ... companies worldwide, released a study today that ... capital-backed biotech and medical device companies. Based ... of US venture-capital backed companies (60 biotech and 58 ...
Cached Medicine Technology:Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 2Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA 3Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 2Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device 3
(Date:7/30/2014)... July 30, 2014 Good Neighbor ... in an upcoming episode of Innovations with Ed ... Channel. Dates and show times TBA. , In ... Neighbor Community Services’ vision to redefine the traditional ... and dynamic services. Through passion, innovation, determination, excellence, ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- It can happen ... television, dresser or computer monitor and gets critically injured ... of a young child should look around their homes and ... a child. Imagining it is better than it becoming a ... Emergency Physicians, said in a college news release. Between ...
(Date:7/30/2014)... as well as evolutionary changes in a living organismhad ... throughout the genome. , However, recent studies have shown ... mutations that arise simultaneously and in close proximity to ... found in regions where chromosomal rearrangements take place. , ... , may one day lead to new cancer therapies, ...
(Date:7/30/2014)... July 30, 2014 Visitors to our ... over $8,500 to ensure its protection. Bob Kiesendahl, one ... check to the Delaware Highlands Conservancy for donations collected ... small $2-per-stay donations add up fast, as visitors welcome ... Upper Delaware River Region. , The Kiesendahl family has ...
(Date:7/30/2014)... 2014) The phrase "we caught it early" is possibly ... midst of a cancer diagnosis. Combating cancer in its ... certain part of the body, gives patients the best ... colon, prostate and other forms of cancer are touted ... providers recommend cancer screenings as a precautionary measure, especially ...
Breaking Medicine News(10 mins):Health News:Good Neighbor Community Services to be Featured in an Upcoming Episode of Innovations With Ed Begley, Jr. 2Health News:Tip-Over Furniture Can Kill Kids 2Health News:Biologists describe mechanism promoting multiple DNA mutations 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 2Health News:UK psychologist creates patient tool to assist with lung cancer screening decision 3
... July 8 Fate Therapeutics, Inc. ... research on small molecule modulators of the Wnt pathway ... International Society for Stem Cell Research (ISSCR) in Barcelona, ... selected Wnt activators induce the differentiation of mesenchymal stem ...
... ... a name change to Freedom Disability and has expanded its operations into a new corporate ... growth of the business, bringing hundreds of new jobs to the state. , ... Shelton, CT (PRWEB) July 8, 2009 -- ...
... , HUNTINGTON BEACH, Calif., July 8 "You are what you ... what you drink may be as important as what you eat ... and many others, according to Dr. Cheryle Hart, medical advisor for ... . , , One study referred ...
... ... according to Ed Sinson, On-line Forum and Social Networking Representative. , ... Irvine, Calif. (Vocus) July 8, 2009 ... according to Ed Sinson, On-line Forum and Social Networking Representative. , , ,"We ...
... ... Parts Washers are growing in popularity. These parts washers are cost effective and quick ... economic climate. , ... (Vocus) July 8, 2009 -- Midbrook, a Jackson, MI based manufacturer of industrial parts ...
... created using embryonic stem cells for the first time in ... understanding of the causes of infertility. Researchers led ... England Stem Cell Institute (NESCI) have developed a new technique ... the laboratory. The work is published today (8th ...
Cached Medicine News:Health News:Fate Therapeutics to Present Data on Stimulation of Osteogenic Activity Using Small Molecule Modulators of Wnt Pathway 2Health News:National Social Security Disability Advocacy Firm Changes Name to "Freedom Disability" and Acquires 22,000 Square Foot Corporate Headquarters in Shelton, CT 2Health News:National Social Security Disability Advocacy Firm Changes Name to "Freedom Disability" and Acquires 22,000 Square Foot Corporate Headquarters in Shelton, CT 3Health News:Latest Studies Show 'Junk Drinks' Pose as Many Health Threats as 'Junk Food' According to AquaHydrate Medical Advisor 2Health News:Latest Studies Show 'Junk Drinks' Pose as Many Health Threats as 'Junk Food' According to AquaHydrate Medical Advisor 3Health News:Latest Studies Show 'Junk Drinks' Pose as Many Health Threats as 'Junk Food' According to AquaHydrate Medical Advisor 4Health News:Bariatric Advantage Participates in Social Networks 2Health News:Refurbished and Used Industrial Parts Washers Grow in Popularity 2Health News:Human sperm created from embryonic stem cells 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: